Venous Thromboembolism with Combined Oral Contraceptives Based on Estrogen and Progestin Content: A disproportionality analysis of the United States Food and Drug Administration Adverse Event Reporting System database

The authors aimed to compare the rates of venous thromboembolic adverse events associated with different combined oral contraceptives (COCs) based on their estrogen and progestin content, specifically focusing on body-identical estrogens versus ethinyl estradiol (EE). Their analysis of the FDA Adverse Event Reporting System revealed that COCs containing estetrol and 17β-estradiol had lower reporting rates of thromboembolic events compared to EE-based pills, indicating a potentially safer thrombotic profile for these body-identical estrogen formulations.